Trump's Tariff Impact: Zydus Life, Aurobindo Pharma, Dr Reddy's Drag Nifty Pharma Lower; Lupin Bucks The Trend
Shares of Indian pharmaceutical companies came under pressure on Thursday after US President Donald Trump announced an additional 25% tariff on Indian exports to the United States, bringing the total rate to 50%.
While the pharma sector remains exempt for now, In an earlier post, Trump indicated via a post on Truth Social that duties on drug exports are likely to be introduced soon.
Nifty Pharma dropped 0.66% intraday, as it underperformed the benchmark Nifty 50, which dropped 0.46% intraday.
Major players such as Zydus Life, Sun Pharma, Dr. Reddy's Laboratories, Cipla, Divi's Laboratories, Aurobindo Pharma, and Biocon declined.
Meanwhile, Lupin was the only drugmaker that defied the pharma stock declines. The stock rose 0.2% during the trade.

The US is a key market for Indian drugmakers. Currently, generic medicines exported from India to the US attract zero tariffs. However, the exemption, granted under reciprocal trade measures, is under review, and the US Department of Commerce has concluded its investigation.
If the proposed 50% tariff is extended to pharmaceutical exports, it could significantly impact margins and competitiveness for Indian firms.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.